Business Wire

IDEMIA Acquires X Core Technologies’ Metal Payment Card Business and Launches Smart Metal Art Offer

17.10.2019 10:40:00 EEST | Business Wire | Press release

Share

At a time when demand for metal payment cards increases, IDEMIA, the global leader in Augmented Identity, broadens its existing offer with Smart Metal Art, a new metal payment card range fully suitable for contactless payments. Smart Metal Art comes from the acquisition of X Core’s metal payment card business and associated patents. Smart Metal Art is designed for the dual interface mass affluent market and is already certified by Visa, Mastercard and Amex.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191017005283/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

In a business environment with both online and offline offerings, metal payment cards have been massively adopted by users representing a booming market. A 2018 global consumer study indicated that more than 50% of consumers are willing to pay for a metal card, 70% of whom are under the age of 351. Fintech firms have nearly all adopted metal payment cards and major banks are also providing metal cards to their high net worth customers.

To satisfy this growing demand while still delivering the convenience customers expect, IDEMIA is investing to expand its leading offer of metal cards and launching Smart Metal Art suite of products. Smart Metal Art is the very first metal payment card fully suitable for contactless payments with no restrictions. It offers endless graphical possibilities thanks to its non-magnetic, decorated metal core, protected by layers that can be transparent or printed.

Smart Metal Art includes patented technology, developed by US firm X Core and recently acquired by IDEMIA. These patents allow for perfect dual interface performance, as well as decoration capabilities, which are then encapsulated within protective layers. Smart Metal Art will be manufactured by IDEMIA in our Exton (Pennsylvania, USA) facility.

At a time when banks need to differentiate strongly from one another, this game-changing technology gives them free reign over their card designs while allowing them to use unrivaled graphics such as etching or a brushed look combined with high-definition coloring techniques on their metal cards.

Thanks to this proprietary technology, IDEMIA will enable even more financial institutions to distribute its latest-generation dual-interface metal payment cards to premium customers, in volume around the world. IDEMIA’s end-to-end contactless metal card offer encompasses design, manufacture, personalization and product packaging.

Smart Metal Art has been certified by Visa, Mastercard and Amex, with no restriction on contactless performance, giving IDEMIA’s clients the opportunity of a very rapid go-to-market for their metal cards.

Amanda Gourbault, Executive Vice-President for Financial Institutions activities at IDEMIA said: “Payment cards are the latest marketing asset for banks for customer acquisition. Acquiring X Core is entirely consistent with IDEMIA’s strategy to offer cutting-edge technology to its customers without ever compromising on security or convenience. Our new offer, Smart Metal Art, delivers the best high-end cards combined with unmatched contactless payment features, which will be a game changer for end-users.

About IDEMIA

IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With 13,000 employees around the world, IDEMIA serves clients in 180 countries.

For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter

About X Core Technologies LLC,

X Core Technologies LLC, is a US based enterprise providing Hot Lamination compatible Prelaminate Core Sheets incorporating advanced electronic functionality for the Payment, Security and Health Care sectors.

For more information, please visit www.X-Coretchnologies.com

----------

1 Phoenix Synergistic, 2016

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For business information, please contact:
Tim Wright, VP Metal Card and Advanced Card Bodies
Timothy.WRIGHT@idemia.com

Press
Hanna SEBBAH - idemia@havas.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release

Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye